Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Trial of CD3/CD28 Activated Id-KLH Primed Autologous Lymphocytes in Subjects With Myeloma Undergoing Autologous Transplant

NCT01426828 is registered in ClinicalTrials.gov with University of Pennsylvania as lead sponsor.

NCT NCT01426828
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01426828 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Trial of CD3/CD28 Activated Id-KLH Primed Autologous Lymphocytes in Subjects With Myeloma Undergoing Autologous Transplant
Lead sponsor
University of Pennsylvania
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2011
Completion date
December 31, 2017
Enrollment
40 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma